NASDAQ · SENS

Senseonics Holdings, Inc.

$5.01 +$0.15 (+3.09%) 1D Pre-market

Key Metrics

$253.71M
Market cap
P/E · TTM
$40.71M
Revenue · TTM
−$87.19M
Net income
EPS · TTM $-2.43
Dividend yield
Free cash flow −$75.87M
Beta · 1Y 2.20
EBITDA · TTM −$85.02M
Gross margin 52.1%

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 22
    From its Feb 26 high, the share price fell 42%.

    Peak close $8.35 on Feb 26; trough close $4.86 on Jul 22. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -42%
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 20.3 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • May 1
    The stock moved -22.8% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, May 1
  • Mar 3
    The stock moved -18.1% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Mar 3

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$253.71M
Enterprise value$225.30M
Shares outstanding52.2M
52-wk range$4.79 – $11.58
Avg volume · 20D512.0K
Net cash $28.41M
Book value / share$0.96
IndustryIndustrial Instruments For Measurement, Display, And Control
ExchangeNASDAQ
About Senseonics Holdings, Inc.
IPO dateMar 18, 2016
Employees130

Senseonics Holdings Inc is a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system to improve the lives of people with diabetes by enhancing their ability to manage their disease with relative ease and accur…

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S6.23
P/FCF
EV/EBITDA
EV/Sales5.53
Graham №

Profitability

Gross 52.1%
Operating -213.0%
Net -214.2%
FCF -186.4%
ROE / ROIC -980.7% · —

Financial Health

Current ratio3.51
Quick ratio3.19
Debt / equity1.05
Debt / EBITDA -0.42
Net cash $28.41M
Working capital$65.96M

Cash Flow · TTM

Operating CF −$75.07M
Capex −$793.00K
Free cash flow −$75.87M
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

6 / 9
Middling fundamentals · 6 of 9 signals passing

Altman Z-Score

-13.7
Distress zone (< 1.81) · elevated risk

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings